Low-dose endotoxin inhalation in healthy volunteers - a challenge model for early clinical drug development

BMC Pulmonary Medicine

Volumn 13, Issue 1, 2013, Pages

  Janssen, Ole ^a,b   Schaumann, Frank ^a   Holz, Olaf ^a,d   Lavae Mokhtari, Bianca ^a,b   Welker, Lutz ^c   Winkler, Carla ^a,b   Biller, Heike ^a   Krug, Norbert ^a,d   Hohlfeld, Jens M ^a,b,d  

^a FRAUNHOFER INSTITUTE FOR TOXICOLOGY AND EXPERIMENTAL MEDICINE   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c Member of the German Center for Lung Research   (Germany)

^d Member of the German Center for Lung Research   (Germany)

Author keywords

Airway inflammation; Induced sputum; Reproducibility; Sputum flow cytometry; Sputum monocytes

Indexed keywords

ANTIINFLAMMATORY AGENT; BACTERIUM LIPOPOLYSACCHARIDE; ROFLUMILAST;

ADULT; ARTICLE; FEMALE; FLOW CYTOMETRY; HUMAN; MALE; MONOCYTE; NEUTROPHIL COUNT; NORMAL HUMAN; REPRODUCIBILITY; RESPIRATORY TRACT INFLAMMATION; SPUTUM ANALYSIS;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AMINOPYRIDINES; BENZAMIDES; CYCLOPROPANES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; ENDOTOXINS; FEMALE; HUMAN EXPERIMENTATION; HUMANS; LIPOPOLYSACCHARIDES; MALE; MIDDLE AGED; MONOCYTES; NEUTROPHILS; PHOSPHODIESTERASE 4 INHIBITORS; PNEUMONIA; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; SPUTUM; YOUNG ADULT;

EID: 84875311082     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/1471-2466-13-19     Document Type: Article

References (32)

1. Rylander R. Endotoxin in the environment-exposure and effects. J Endotoxin Res 2002, 8:241-252.
2. Hasday JD, Bascom R, Costa JJ, Fitzgerald T, Dubin W. Bacterial endotoxin is an active component of cigarette smoke. Chest 1999, 115:829-835. 10.1378/chest.115.3.829, 10084499.
3. Carty CL, Gehring U, Cyrys J, Bischof W, Heinrich J. Seasonal variability of endotoxin in ambient fine particulate matter. J Environ Monit 2003, 5:953-958. 10.1039/b308488d, 14710938.
4. Hohlfeld JM, Schoenfeld K, Lavae-Mokhtari M, Schaumann F, Mueller M, Bredenbroeker D, Krug N, Hermann R. Roflumilast attenuates pulmonary inflammation upon segmental endotoxin challenge in healthy subjects: a randomized placebo-controlled trial. Pulm Pharmacol Ther 2008, 21:616-623. 10.1016/j.pupt.2008.02.002, 18374614.
5. O'Grady NP, Preas HL, Pugin J, Fiuza C, Tropea M, Reda D, Banks SM, Suffredini AF. Local inflammatory responses following bronchial endotoxin instillation in humans. Am J Respir Crit Care Med 2001, 163:1591-1598. 10.1164/ajrccm.163.7.2009111, 11401879.
6. Michel O, Nagy AM, Schroeven M, Duchateau J, Neve J, Fondu P, Sergysels R. Dose-response relationship to inhaled endotoxin in normal subjects. Am J Respir Crit Care Med 1997, 156:1157-1164. 10.1164/ajrccm.156.4.97-02002, 9351616.
7. Thorn J. The inflammatory response in humans after inhalation of bacterial endotoxin: a review. Inflamm Res 2001, 50:254-261. 10.1007/s000110050751, 11409488.
8. Alexis NE, Lay JC, Almond M, Bromberg PA, Patel DD, Peden DB. Acute LPS inhalation in healthy volunteers induces dendritic cell maturation in vivo. J Allergy Clin Immunol 2005, 115:345-350. 10.1016/j.jaci.2004.11.040, 15696093.
9. Hernandez ML, Harris B, Lay JC, Bromberg PA, Diaz-Sanchez D, Devlin RB, Kleeberger SR, Alexis NE, Peden DB. Comparative airway inflammatory response of normal volunteers to ozone and lipopolysaccharide challenge. Inhal Toxicol 2010, 22:648-656. 10.3109/08958371003610966, 3162474, 20540623.
10. Loh LC, Vyas B, Kanabar V, Kemeny DM, O'Connor BJ. Inhaled endotoxin in healthy human subjects: a dose-related study on systemic effects and peripheral CD4+ and CD8+ T cells. Respir Med 2006, 100:519-528. 10.1016/j.rmed.2005.06.003, 16039108.
11. Michel O, Ginanni R, Le BB, Content J, Duchateau J, Sergysels R. Inflammatory response to acute inhalation of endotoxin in asthmatic patients. Am Rev Respir Dis 1992, 146:352-357. 10.1164/ajrccm/146.2.352, 1489124.
12. Alexis NE, Brickey WJ, Lay JC, Wang Y, Roubey RA, Ting JP, Peden DB. Development of an inhaled endotoxin challenge protocol for characterizing evoked cell surface phenotype and genomic responses of airway cells in allergic individuals. Ann Allergy Asthma Immunol 2008, 100:206-215. 10.1016/S1081-1206(10)60444-9, 18426139.
13. Kitz R, Rose MA, Borgmann A, Schubert R, Zielen S. Systemic and bronchial inflammation following LPS inhalation in asthmatic and healthy subjects. J Endotoxin Res 2006, 12:367-374. 10.1179/096805106X153934, 17254391.
14. Aul R, Armstrong J, Duvoix A, Lomas D, Hayes B, Miller BE, Jagger C, Singh D. Inhaled LPS challenges in smokers: a study of pulmonary and systemic effects. Br J Clin Pharmacol 2012, 74(6):1023-32. 10.1111/j.1365-2125.2012.04287.x, 22469312.
15. Maris NA, de Vos AF, Dessing MC, Spek CA, Lutter R, Jansen HM, van der Zee JS, Bresser P, van der Poll T. Antiinflammatory effects of salmeterol after inhalation of lipopolysaccharide by healthy volunteers. Am J Respir Crit Care Med 2005, 172:878-884. 10.1164/rccm.200503-451OC, 15994467.
16. Wallin A, Pourazar J, Sandstrom T. LPS-induced bronchoalveolar neutrophilia; effects of salmeterol treatment. Respir Med 2004, 98:1087-1092. 10.1016/j.rmed.2004.03.025, 15526809.
17. Michel O, Dentener M, Cataldo D, Cantinieaux B, Vertongen F, Delvaux C, Murdoch RD. Evaluation of oral corticosteroids and phosphodiesterase-4 inhibitor on the acute inflammation induced by inhaled lipopolysaccharide in human. Pulm Pharmacol Ther 2007, 20:676-683. 10.1016/j.pupt.2006.08.002, 17045826.
18. Doyen V, Kassengera Z, Dinh DH, Michel O. Time course of endotoxin-induced airways' inflammation in healthy subjects. Inflammation 2010, 35:33-38.
19. Djukanovic R, Sterk PJ, Fahy JV, Hargreave FE. Standardised methodology of sputum induction and processing. Eur Respir J 2002, 20:1S-55S.
20. Brand P, Friemel I, Meyer T, Schulz H, Heyder J, Haubetainger K. Total deposition of therapeutic particles during spontaneous and controlled inhalations. J Pharm Sci 2000, 89:724-731. 10.1002/(SICI)1520-6017(200006)89:6<724::AID-JPS3>3.0.CO;2-B, 10824130.
21. Holz O, Tal-Singer R, Kanniess F, Simpson KJ, Gibson A, Vessey RS, Janicki S, Magnussen H, Jorres RA, Richter K. Validation of the human ozone challenge model as a tool for assessing anti-inflammatory drugs in early development. J Clin Pharmacol 2005, 45:498-503. 10.1177/0091270004273527, 15831772.
22. Fleiss JL. Design and Analysis of Clinical Experiments 1986, 8-13. New York: Wiley-Interscience.
23. Lay JC, Peden DB, Alexis NE. Flow cytometry of sputum: assessing inflammation and immune response elements in the bronchial airways. Inhal Toxicol 2011, 23:392-406. 10.3109/08958378.2011.575568, 21639708.
24. Fan H, Cook JA. Molecular mechanisms of endotoxin tolerance. J Endotoxin Res 2004, 10:71-84.
25. West MA, Heagy W. Endotoxin tolerance: A review. Crit Care Med 2002, 30:S64-S73. 10.1097/00003246-200201001-00009, 11891406.
26. Kharitonov SA, Sjobring U. Lipopolysaccharide challenge of humans as a model for chronic obstructive lung disease exacerbations. Contrib Microbiol 2007, 14:83-100.
27. Loh LC. Tolerance to repeat exposure of inhaled endotoxin: an observation in healthy humans. Eur Respir J 2005, 26:363-364. 10.1183/09031936.05.00058405, 16055890.
28. Lahu G, Hunnemeyer A, Diletti E, Elmlinger M, Ruth P, Zech K, McCracken N, Facius A. Population pharmacokinetic modelling of roflumilast and roflumilast N-oxide by total phosphodiesterase-4 inhibitory activity and development of a population pharmacodynamic-adverse event model. Clin Pharmacokinet 2010, 49:589-606. 10.2165/11536600-000000000-00000, 20690782.
29. Hermann R, Siegmund W, Giessmann T, Westphal K, Weinbrenner A, Hauns B, Reutter F, Lahu G, Zech K, Bethke TD. The oral, once-daily phosphodiesterase 4 inhibitor roflumilast lacks relevant pharmacokinetic interactions with inhaled budesonide. J Clin Pharmacol 2007, 47:1005-1013. 10.1177/0091270007300950, 17660483.
30. Seehase S, Lauenstein HD, Schlumbohm C, Switalla S, Neuhaus V, Forster C, Fieguth HG, Pfennig O, Fuchs E, Kaup FJ. LPS-induced lung inflammation in marmoset monkeys - an acute model for anti-inflammatory drug testing. PLoS One 2012, 7:e43709. 10.1371/journal.pone.0043709, 3429492, 22952743.
31. Grootendorst DC, Gauw SA, Verhoosel RM, Sterk PJ, Hospers JJ, Bredenbroker D, Bethke TD, Hiemstra PS, Rabe KF. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 2007, 62:1081-1087. 10.1136/thx.2006.075937, 2094292, 17573446.
32. Gauvreau GM, Boulet LP, Schmid-Wirlitsch C, Cote J, Duong M, Killian KJ, Milot J, Deschesnes F, Strinich T, Watson RM. Roflumilast attenuates allergen-induced inflammation in mild asthmatic subjects. Respir Res 2011, 12:140. 10.1186/1465-9921-12-140, 3219708, 22029856.